applsci-logo

Journal Browser

Journal Browser

Novel Insight into Mechanisms of Bioactive Compounds and Its Use in the Prevention and Treatment of Thromboinflammation

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".

Deadline for manuscript submissions: closed (25 August 2022) | Viewed by 6789

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmacology, Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
Interests: cardiovascular pharmacology; protein bio—chemistry; signal transduction; platelet biology; anti-thrombotic drug development
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The close connection between inflammatory and thrombotic processes is presumed to have an evolutionary origin, as injuries need both an efficient hemostasis and an inflammatory immune response against entering pathogens. Behind vasoconstriction, platelets are the first immunomodulatory cells at the side of injury closing damaged blood vessels by aggregation and forming a thrombus. Thus, platelets promote inflammatory activity by an intimate crosstalk with leukocytes: in the case of vascular injury, neutrophils or monocytes are suggested to interact with endothelium-adherent platelets. Thus, platelets coordinate the inflammatory response by controlling the additional adhesion of innate immune cells to the inflamed endothelium, which is considered serious for the atherosclerotic disease process. For example, macrophage pro-inflammatory cytokine secretion is enhanced following interaction with activated platelets, proposing that the presence of activated platelets at sites of inflammation aggravates pro-inflammatory macrophage activation. The diversity of platelet receptors contributing to platelet interactions reveals various interesting targets within the context of platelet-mediated inflammation. Since a broad range of recent experimental methodologies indicate that platelets contribute to the pathogenesis of stroke-associated inflammation, the targeting of inhibiting mechanisms, which is involved in platelet activation, thromboembolism and its related inflammation is important to prevent thromboinflammatory diseases. Although many natural phytomedicine with potent anti-inflammatory properties have been noted as reasonable approaches for clinical trials, inadequate effort has been directed towards finding the molecular mechanisms underlying the therapeutic efficacy against thromboinflammatory events. Therefore, we invite authors to contribute their original research as well as review articles focused on understanding the molecular mechanisms of natural or synthetic bioactives on antithrombotic and inflammatory responses.

Potential topics include but are not limited to:

  • Antiplatelet and antithrombotic mechanism of bioactive compounds;
  • anti-inflammatory role and therapeutic mechanism of natural bioactives;
  • the neuroprotective role of bioactive substances.

Prof. Dr. Joen-Rong Sheu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioactive compounds
  • phytomedicines
  • antiplatelet
  • thromboinflammation
  • neuroprotection

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2809 KiB  
Article
Metformin Serves as a Novel Drug Treatment for Arterial Thrombosis: Inhibitory Mechanisms on Collagen-Induced Human Platelet Activation
by Yi Chang, Wei-Chieh Huang, Chia-Yuan Hsu, Chih-Wei Hsia, Thanasekaran Jayakumar, Cheng-Ying Hsieh, Wan-Jung Lu and Chao-Chien Chang
Appl. Sci. 2022, 12(15), 7426; https://doi.org/10.3390/app12157426 - 24 Jul 2022
Cited by 1 | Viewed by 2525
Abstract
Metformin is widely used as first-line medication for type 2 diabetes (T2D), the main disease comorbid with kidney disease, cardiovascular diseases (CVDs), and retinopathy. Platelets are crucial in platelet-dependent arterial thrombosis, which causes CVDs and cerebrovascular diseases. Research indicates that metformin may improve [...] Read more.
Metformin is widely used as first-line medication for type 2 diabetes (T2D), the main disease comorbid with kidney disease, cardiovascular diseases (CVDs), and retinopathy. Platelets are crucial in platelet-dependent arterial thrombosis, which causes CVDs and cerebrovascular diseases. Research indicates that metformin may improve these diseases; metformin reportedly reduced platelet activation in rats. However, no reports have included human platelets. We investigated the mechanisms underlying metformin’s effects on platelet activation by using human platelets and evaluated its in vivo effectiveness in experimental mice. Metformin inhibited platelet aggregation stimulated by collagen but not by arachidonic acid, U46619, or thrombin. Metformin suppressed ATP release, [Ca2+]i mobilization, and P-selectin expression, as well as phospholipase C (PLC)γ2/protein kinase C (PKC), p38 mitogen-activated protein kinase (MAPK), and phosphoinositide 3-kinase (PI3K)/Akt/glycogen synthase kinase-3β (GSK3β) phosphorylation. Metformin did not affect vasodilator-stimulated phosphoprotein (VASP) phosphorylation. In the animal studies, metformin reduced acute pulmonary thromboembolism mortality without increasing bleeding times. These results provide insights into the role and mechanisms of metformin in human platelet activation. Metformin decreased platelet activation by interfering with the PLCγ2/PKC, PI3K/Akt/GSK3β, and p38 MAPK pathways through a VASP-independent mechanism. Metformin demonstrates promise as a new class of antiplatelet agent that can inhibit platelet activation. Full article
Show Figures

Figure 1

13 pages, 653 KiB  
Article
The Association between Influenza Vaccination and Stroke Risk in Patients with Hypertension: A Nationwide Population-Based Study
by Cheng-Hsin Lin, Chun-Chih Chiu, Tsung-Yeh Yang, Yu-Ann Fang, Meng-Huan Lei, Hsien-Tang Yeh, Chun-Chao Chen, Wen-Rui Hao, Chung-Hsien Kuo and Ju-Chi Liu
Appl. Sci. 2022, 12(8), 4074; https://doi.org/10.3390/app12084074 - 18 Apr 2022
Viewed by 1871
Abstract
There is evidence of strong association between influenza infections and stroke; however, the influenza vaccination and its effect on strokes is currently unclear. In the present study, Taiwan’s National Health Insurance Database was used in obtaining data for study subjects 55 years and [...] Read more.
There is evidence of strong association between influenza infections and stroke; however, the influenza vaccination and its effect on strokes is currently unclear. In the present study, Taiwan’s National Health Insurance Database was used in obtaining data for study subjects 55 years and older diagnosed with hypertension (n = 59,251; 25,266 vaccinated and 33,985 unvaccinated subjects) from 2001–2012. Propensity scores were calculated using a logistic regression model to determine the effects of vaccination by accounting for covariates that predict receiving the intervention (vaccine). A time-dependent Cox proportional hazard model was used to calculate the hazard ratios (HRs) for stroke in vaccinated and unvaccinated patients. Influenza vaccination was associated with a 42%, 40% and 44% stroke risk reduction in the entire cohort for all seasons, the influenza season and the non-influenza season, respectively (Adjust hazard ratio [aHR]: 0.58, 95% confidence interval [CI]: 0.56–0.61; aHR: 0.60, 95% CI: 0.56–0.63; aHR: 0.56, 95% CI: 0.52–0.60, for all seasons, the influenza season and the non-influenza season, respectively). The effect of risk reduction by vaccination also revealed a trend of dose dependency. Among subjects between 55 to 64 years old with four or more vaccinations during the study period, there is a 73% risk reduction for stroke during the non-influenza season (aHR: 0.27, 95% CI: 0.20–0.34). In conclusion, the influenza vaccination exerts dose-dependent and synergistic protective effects against stroke in individuals 55 years and older with hypertension. Full article
Show Figures

Figure 1

Review

Jump to: Research

10 pages, 1958 KiB  
Review
Anti-Inflammatory Mechanisms of Novel Synthetic Ruthenium Compounds
by Thanasekaran Jayakumar, Joen-Rong Sheu, Chih-Wei Hsia, Periyakali Saravana Bhavan and Chao-Chien Chang
Appl. Sci. 2021, 11(21), 10092; https://doi.org/10.3390/app112110092 - 28 Oct 2021
Cited by 5 | Viewed by 1823
Abstract
Inflammation is the primary biological reaction to induce severe infection or injury in the immune system. Control of different inflammatory cytokines, such as nitric oxide (NO), interleukins (IL), tumor necrosis factor alpha-(TNF-α), noncytokine mediator, prostaglandin E2 (PGE2), mitogen activated protein kinases (MAPKs) and [...] Read more.
Inflammation is the primary biological reaction to induce severe infection or injury in the immune system. Control of different inflammatory cytokines, such as nitric oxide (NO), interleukins (IL), tumor necrosis factor alpha-(TNF-α), noncytokine mediator, prostaglandin E2 (PGE2), mitogen activated protein kinases (MAPKs) and nuclear factor kappa B (NF-κB), facilitates anti-inflammatory effect of different substances. Coordination metal complexes have been applied as metallo-drugs. Several metal complexes have found to possess potent biological activities, especially anticancer, cardioprotective, chondroprotective and anti-parasitosis activities. Among the metallo drugs, ruthenium-based (Ru) complexes have paid much attention in clinical applications. Despite the kinetic nature of Ru complexes is similar to platinum in terms of cell division events, their toxic effect is lower than that of cisplatin. This paper reviews the anti-inflammatory effect of novel synthetic Ru complexes with potential molecular mechanisms that are actively involved. Full article
Show Figures

Figure 1

Back to TopTop